EXPERIENCE OF THE USE OF DRUG UROREC: EFFICACY AND SAFETY
- Autores: Kadiev R.M1, Derevyanko T.I1
-
Afiliações:
- Stavropol State Medical Academy
- Edição: Nº 3 (2014)
- Páginas: 44-47
- Seção: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/280194
- ID: 280194
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The article presents the experience of use of the new superselective α-blocker urorec (silodosin ) in the treatment of 30 patients with lower urinary tract symptoms aged 49 to 69 years. Patients have received silodosin 1 capsule a day for 2 months. According to the results of study, silodosin has demonstrated high efficacy and an acceptable safety profile. It was shown that silodosin does not increase the risk of hypotension in patients taking antihypertensive medications. Therapy with silodosin had positive and statistically significant impact on subjective and objective symptoms of the disease, which was confirmed by the IPSS-QoL score and uroflowmetry. Silodosin has rapid onset of effect (3-4 days after the start of treatment); it can be used in all patients suffering from BPH and having indications to the administration of α-blockers, and does not require correction of doses of antihypertensive drugs in the case of combined appointment.
Texto integral
Sobre autores
R. Kadiev
Stavropol State Medical AcademyDepartment of Urology, Pediatric Urology, Andrology with the course of Radiology
T. Derevyanko
Stavropol State Medical Academy
Email: uro-dep@yandex.ru
Professor, Head of the Department of Urology, Pediatric Urology, Andrology with the course of Radiology; doctor of the highest qualification category
Bibliografia
- Лопаткин Н.А., Перепанова Т.С. Клинический опыт лечения больных доброкачественной гиперплазией предстательной железы а1-адреноблокатором альфузозином. Урол. и нефрол. 1997. № 5. С. 14-17.
- Гориловский Л.М. Доброкачественная гиперплазия предстательной железы. Под ред. Н.А. Лопаткина. М, 1997. С. 10-18.
- Шаплыгин Л.В., Стеблюкова И. А. Terra medica-nova. 1998. № 1. С. 30-31.
- Доброкачественная гиперплазия предстательной железы. Под ред. Н.А. Лопаткина. М. 1999. 216 с.
- Аляев Ю.Г. Диагностика и лечение доброкачественной гиперплазии предстательной железы. Лечащий врач. 2007. № 4. C. 70-72.
- Peters T.J., Donovan J.L., Kay H.E. et al. The International Continence Society «Benign Prostatic Hyperplasia» Study: the botherosomeness of urinary symptoms. J Urol. 1997;157:885-889.
- Oelke M., Bachmann A., Descazeaud A. et al. EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. EUROPEAN UROLOGY. 64; (2013): 118-140.
- Milani S., Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest updated on α -adrenoceptor antagonists. BJU Int. 2005. Vol. 95. Suppl 4. P. 29-36.
- Яровой С.К. Силодозин - новый препарат группы селективных α -адреноблокаторов. Экспериментальная и клиническая урология. 2012. № 3.
- Суриков В.Н. Сравнительная оценка эффективности и безопасности применения α -адреноблокаторов у больных доброкачественной гиперплазией предстательной железы. Дисс. к.м.н. М. 2004. С. 1-34.
- Суриков В.Н., Ивлева А.Я., Максименко О.К. и др. Сравнительная оценка безопасности различных α -адреноблокаторов у больных доброкачественной гиперплазией предстательной железы. Клиническая фармакология и терапия, 2003 Т. 12. № 4. С. 32-35.
- Van Dijk M.M., de la Rosette JJMCH, Michel M.C. Tamsulosin - modifi ed-release and oral-controlled absorption system formulation in the treatment of benign prostatic hyperplasia. Therapy. 2006. Vol. 3. P. 237-246.
- Nickel J.C., Sander S., Moon T.D. A-meta-analysis of the vascular-related safety profile and efficacy of a-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract. 2008. Vol. 62. P. 1547-1559.
Arquivos suplementares
